|Table of Contents|

Serum metabolomics study on the effect of Fuzheng Kangai Formula on liver cancer with liver stagnation,spleen deficiency,stasis and toxin syndrome

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1669-1677
Research Field:
Publishing date:

Info

Title:
Serum metabolomics study on the effect of Fuzheng Kangai Formula on liver cancer with liver stagnation,spleen deficiency,stasis and toxin syndrome
Author(s):
CUI Yi1; ZHANG Jiao1; ZHAO Peixi1; YUAN Bin1; XU Jianqin2; ZHAO Bin1; HAN Le1; CHEN Wenjuan1; CHEN Zhenghong1; ZHANG Yili1
1.Shaanxi Cancer Hospital,Shaanxi Xi'an 710061,China;2.Shaanxi Traditional Chinese Medicine Hospital,Shaanxi Xi'an 710003,China.
Keywords:
Fuzheng Kangai Formula; liver cancer; metabolomics; differential metabolites
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2024.09.017
Abstract:
Objective:To explore the effects of Fuzheng Kangai Formula on serum metabolic abnormalities,potential biomarkers,and metabolic pathways in patients with liver cancer with liver stagnation,spleen deficiency,and stasis toxin syndrome.Methods:Twelve healthy subjects and primary liver cancer patients who came to a hospital from May 2021 to July 2022 were selected as the research subjects.Serum samples of healthy individuals and liver cancer patients before and after treatment with Fuzheng Kangai Formula were collected,and full spectrum metabolomics analysis was performed using ultra-high performance liquid chromatography and tandem mass spectrometry.Principal component analysis,least squares discriminant analysis,and univariate statistical analysis were used to determine the content of relevant metabolic markers.Results:The study included serum samples from 36 patients,including 12 healthy control group and 12 cases before and after the intervention of Fuzheng Kangai Formula.The metabolomics results suggest that a total of 570 differential metabolites were screened from the healthy control group and the pre-treatment group with Fuzheng Kangai Formula.There are a total of 571 differential metabolites between the healthy control group and the post-treatment group with Fuzheng Kangai Formula.There are a total of 74 differential metabolites before and after the intervention of Fuzheng Kangai Formula,of which 37 are upregulated,37 are downregulated,and 14 are significantly different metabolites,mainly enriched in the metabolism of ascorbic acid and arabinose,phenylalanine metabolism,cofactor biosynthesis,inositol phosphate metabolism,and the biosynthesis pathways of valine leucine and isoleucine.Conclusion:This study screened 14 differential metabolites that showed significant changes before and after treatment,and analyzed the main enrichment pathways,regulatory networks,and mechanisms of action of these metabolites.From the perspective of integrated traditional Chinese and Western medicine,new insights were provided for the mechanism of action of Fuzheng Kangai Formula in treating liver cancer patients with advanced liver stagnation,spleen deficiency,and stasis toxin syndrome.

References:

［1]徐蓉,华忠.肝硬化并发原发性肝癌的流行病学特征、危险因素及相关预防干预对策研究［J］.中西医结合肝病杂志,2020,30(04):357-359． XU R,HUA Z.Epidemiological characteristics,risk factors and related preventive intervention strategies for cirrhosis complicated with primary liver cancer［J］.Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases,2020,30(04):357-359．
［2]曹艳,王艳.基于死因监测青岛市居民 2008-2012 年原发性肝癌死亡分析［J］.中华肿瘤防治杂志，2017，24(9):579-583． CAO Y,WANG Y.Mortality analysis of primary liver cancer in Qingdao city residents during 2008-2012 based on the cause of desth［J］.Chin J Cancer Prev Treat，2017，24(9):579-583．
［3]ZENG HM，CHEN WQ，ZHENG RS，et al.Changing cancer survival in China during 2003-15：a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health，2018，6(5)：e555-e567.
［4]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南［J］.中华肝脏病杂志,2022,30(04):367-388. Medical Administration and Medical Governance Bureau of the National Health Commission of the People's Republic of China.Guidelines for the diagnosis and treatment of primary liver cancer ［J］.Chinese Journal of Hepatology,2022,30(04):367-388.
［5]赵培西,许建秦,袁彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究［J］.陕西中医,2022,43(12):1746-1748. ZHAO PX,XU JQ,YUAN B,et al.Clinical study on the effect of Fuzheng Kangai Formula on liver cancer with liver stagnation,spleen deficiency,stasis and toxin syndrome［J］.Shaanxi Journal of Traditional Chinese Medicine,2022,43(12):1746-1748.
［6]BARRON KA,JEFFRIES KA,KRUPENKO NI.Sphingolipids and the link between alcohol and cancer［J］.Chem Biol Interact,2020,322:109058.
［7]张荣杰,周格,李福阳,等.基于生物信息学分析筛选和鉴定肝细胞癌预后相关的代谢基因［J］.现代肿瘤医学,2022,30(05):860-869. ZHANG RJ,ZHOU G,LI FY,et al.Bibliometric analysis of liver cancer metabolism research based on［J］.Modern Oncology,2022,30(05):860-869.
［8]李晶洁,刘述梅,王东,等.基于UPLC-MS的肝癌脾虚湿盛证患者血浆代谢组学研究［J］.中国中医基础医学杂志,2021,27(07):1132-1133. LI JJ,LIU SM,WANG D,et al.Study on the plasma metabolism of liver cancer patients with spleen deficiency and dampness syndrome based on UPLC-MS［J］.Journal of Basic Chinese Medicine,2021,27(07):1132-1133.
［9]GANESAN R,YOON SJ,SUK KT,et al.Microbiome and metabolomics in liver cancer:Scientific technology［J］.Int J Mol Sci,2022,24(1):537.
［10]巴合沙拉·马乃甫,尤力都孜·买买提,玉素甫江·艾力,等.土大黄根提取物对银屑病模型小鼠血清代谢组学指标的影响［J］.中国药业,2023,32(5):40-46. MANAP B,MAMAT Y,ALI Y,et al. Effect of rumicis obtusifolii radix extract on serum metabolomics indexes of model mice with psoriasis［J］. China Pharmaceuticals,2023,32(5):40-46.
［11］王林琳,孙振亮.氨基酸转运体在肿瘤代谢中的研究进展［J］.生物技术进展,2022,12(01):50-56. WANG LL,SUN ZL.Research progress of amino acid transporters in tumor metabolism ［J］.Advances in Biotechnology,2022,12(01):50-56.
［12］程美玉,郑心子,李娜.LncRNA-HOTAIR与肿瘤代谢重编［J］.国际遗传学杂志,2018,41(06):490-496. CHENG MY,ZHENG XZ,LI N.LncRNA-HOTAIR and tumor metabolic reprogramming［J］.International Journal of Genetics,2018,41(06):490-496.
［13]MUTHUSAMY T,CORDES T,HANDZLIK MK,et al.Serine restriction alters sphingolipid diversity to constrain tumour growth［J］.Nature,2020,586(7831):790-795.
［14]LIU DH,WEN GM,SONG CL,et al.Amino acid profiles in the tissue and serum of patients with liver cancer［J］.Open Med (Wars),2022,17(1):1797-1802.
［15]SIKALIDIS AK.Amino acids and immune response:A role for cysteine,glutamine,phenylalanine,tryptophan and arginine in T-cell function and cancer［J］.Pathol Oncol Res,2015,21(1):9-17.
［16]LI W,TAN M,WANG H,et al.METTL3-mediated m6A mRNA modification was involved in cadmium-induced liver injury［J］.Environ Pollut,2023,331(Pt 2):121887.
［17]JIANG X,LI W,TAN M,et al.Identification of miRNAs involved in liver injury induced by chronic exposure to cadmium［J］.Toxicology,2022,469:153133.
［18]LIU X,LI M,WANG X,et al.Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis［J］.Lipids Health Dis,2018,17(1):248-258.
［19]LI G,LIU D,KIMCHI ET,et al.Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice［J］.Gastroenterology,2018,154(4):1024-1036.
［20]赵培西,唐仕浩,赵斌,等.基于网络药理学探讨扶正抗癌方治疗肝癌的作用机制［J］.临床医学研究与实践,2022,7(2):16-20. ZHAO PX,TANG SH,ZHAO B,et al.Discussion on the mechanism of Fuzhen Kang'ai formula in the treatment of liver cancer based on network pharmacology［J］.Clinical Research and Practice,2022,7(2):16-20.

Memo

Memo:
陕西省中医药管理局中医药传承创新暨秦药开发项目(编号：2021-01-ZZ-012)； 陕西省科技厅重点研究计划一般项目（编号：2021SF-374）
Last Update: 2024-03-29